Merck Serono points finger at UK oncologists for personalised meds lag
This article was originally published in Clinica
Executive Summary
The UK is lagging far behind Europe in testing cancer patients for biomarkers, with oncologists who are too set in their ways to test for and prescribe innovative drugs the main problem, according to Merck Serono's director of oncology, Rob Drury-Dryden.